718 related articles for article (PubMed ID: 16519039)
1. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
[TBL] [Abstract][Full Text] [Related]
3. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.
Davidson JA; Liebl A; Christiansen JS; Fulcher G; Ligthelm RJ; Brown P; Gylvin T; Kawamori R
Clin Ther; 2009 Aug; 31(8):1641-51. PubMed ID: 19808125
[TBL] [Abstract][Full Text] [Related]
4. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
Hermansen K; Colombo M; Storgaard H; ØStergaard A; Kølendorf K; Madsbad S
Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
[TBL] [Abstract][Full Text] [Related]
5. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus.
McSorley PT; Bell PM; Jacobsen LV; Kristensen A; Lindholm A
Clin Ther; 2002 Apr; 24(4):530-9. PubMed ID: 12017398
[TBL] [Abstract][Full Text] [Related]
6. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
[TBL] [Abstract][Full Text] [Related]
7. Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review.
Gough SC; Tibaldi J
Clin Drug Investig; 2007; 27(5):299-324. PubMed ID: 17451279
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study.
Morgan CL; Evans M; Toft AD; Jenkins-Jones S; Poole CD; Currie CJ
Clin Ther; 2011 Jan; 33(1):27-35. PubMed ID: 21397771
[TBL] [Abstract][Full Text] [Related]
9. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
10. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients.
Boehm BO; Home PD; Behrend C; Kamp NM; Lindholm A
Diabet Med; 2002 May; 19(5):393-9. PubMed ID: 12027927
[TBL] [Abstract][Full Text] [Related]
11. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of biphasic insulin aspart 30 in type 2 diabetes patients switched from either biphasic or basal human insulin: results from the Gulf cohort of the A1 chieve study.
Almansari A; Khader S; Kharawagh A; AbdelFattah W; Badawy T
Int J Clin Pract; 2014 Jul; 68(7):850-6. PubMed ID: 24548757
[TBL] [Abstract][Full Text] [Related]
13. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
15. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.
Gumprecht J; Benroubi M; Borzi V; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y; Ligthelm R; Valensi P;
Int J Clin Pract; 2009 Jun; 63(6):966-72. PubMed ID: 19504715
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
Lim-Abrahan MA; Yu-Gan S; Jain AB; Sobrepena LM; Racho VA
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S35-40. PubMed ID: 23647717
[TBL] [Abstract][Full Text] [Related]
17. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
Rys P; Wojciechowski P; Siejka S; Małecki P; Hak L; Malecki MT
Int J Clin Pract; 2014 Mar; 68(3):304-13. PubMed ID: 24471814
[TBL] [Abstract][Full Text] [Related]
18. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.
Kann PH; Wascher T; Zackova V; Moeller J; Medding J; Szocs A; Mokan M; Mrevlje F; Regulski M
Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):527-32. PubMed ID: 17115351
[TBL] [Abstract][Full Text] [Related]
19. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
[TBL] [Abstract][Full Text] [Related]
20. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
Hussein Z; Lim-Abrahan MA; Jain AB; Goh SY; Soewondo P
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S24-9. PubMed ID: 23647714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]